Treatment of childhood autoimmune haemolytic anaemia with rituximab.

Abstract

Autoimmune haemolytic anaemia commonly has a severe course in young children, thus requiring multiple immunosuppressive treatments. Five children with refractory idiopathic autoimmune haemolytic anaemia, and one child with the disease after bone-marrow transplantation, were treated with rituximab-a monoclonal antibody against CD20. Tolerance of the treatment was good. However, circulating Bcells were absent and hypogammaglobulinaemia was seen for 9 months after treatment. All patients remained in complete remission 15-22 months after the start of rituximab therapy. Corticosteroids and immunosuppressive drugs were stopped or their dose markedly reduced. We suggest that rituximab could be a valuable treatment for autoimmune haemolytic anaemia, although a long-lasting but transient B-cell deficiency develops.

050100150'03'05'07'09'11'13'15'17
Citations per Year

1,089 Citations

Semantic Scholar estimates that this publication has 1,089 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Quartier2001TreatmentOC, title={Treatment of childhood autoimmune haemolytic anaemia with rituximab.}, author={Pierre Quartier and Beno{\^i}t Brethon and Pierre Philippet and Judith Landman-Parker and Françoise le Deist and Alain Fischer}, journal={Lancet}, year={2001}, volume={358 9292}, pages={1511-3} }